Product Description
JNJ-40411813 is a positive allosteric modulator of mGluR2 for the treatment of seizures being developed by Addex and Johnson & Johnson. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25735992/)
Mechanisms of Action: MGLUR2/3 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: Addex Pharma
Clinical Description
Countries in Clinic: Belgium, Germany, Japan, Korea, Poland, Russia, Spain, Ukraine, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Seizures
Phase 1: Epilepsy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| A study to investigate JNJ-40411813 in combination with levetiracetam in epilepsy | P2 |
Active, not recruiting |
Seizures |
2024-06-10 |
|
| CR108943 | P2 |
Completed |
Seizures |
2024-02-08 |
|
| jRCT2071200090 | P1 |
Active, not recruiting |
Epilepsy |
2021-05-25 |